Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $385 | $372 | $350 | $518 |
| - Cash | $56 | $55 | $59 | $55 |
| + Debt | $700 | $699 | $699 | $672 |
| Enterprise Value | $1,029 | $1,017 | $991 | $1,135 |
| Revenue | $38 | $40 | $37 | $39 |
| % Growth | -3.3% | 7% | -5.3% | – |
| Gross Profit | $16 | $15 | -$1 | $10 |
| % Margin | 41.4% | 36.9% | -3.7% | 25.6% |
| EBITDA | -$32 | -$36 | -$52 | $16 |
| % Margin | -84.3% | -89.5% | -139.6% | 41.8% |
| Net Income | -$38 | -$42 | -$426 | $2 |
| % Margin | -98.9% | -105.4% | -1,146.8% | 6% |
| EPS Diluted | -0.13 | -0.14 | -1.44 | 0.008 |
| % Growth | 7.1% | 90.3% | -18,801.3% | – |
| Operating Cash Flow | -$19 | -$29 | -$44 | -$31 |
| Capital Expenditures | $0 | -$1 | -$6 | -$2 |
| Free Cash Flow | -$19 | -$30 | -$50 | -$32 |